Kalev Kask, Ph.D. , Chief Executive Officer
Kalev Kask completed his graduate degree with Prof. Tamas Bartfai at Stockholm University and post-doctoral training with Prof. Peter Seeburg at the Max-Planck Institute for Medical Research in Heidelberg. He then joined the neurogenomics company AGY Therapeutics of South San Francisco as a senior scientist, followed by research at Stanford University and advisory work with Asper Biotech and Toshiba prior to founding EGeen. Dr. Kask has authored numerous scientific publications and has patented genomics derived drug and diagnostic targets.
Ants Prümmel. MBA , General Manager, EGeen AS.
Mr. Prümmel brings several decades of financial and operational management experience to EGeen. He has previously held numerous management positions of increasing responsibility at various financial institutions and in the telecommunications sector. Most recently he served as the Chief Financial Officer and subsequently as Chief Executive Officer at Levicom, a pan-Baltic State telecommunications firm. Upon the acquisition of Levicom by Tele2, a major European telecommunications corporation, he joined EGeen in March 2005 and is responsible for the general management of EGeen AS, a wholly owned subsidiary of EGeen International.
Elizabeth S. Song, Ph.D. , Vice President, Business Development
Elizabeth Song obtained her M.A. in Immunology from University of California, Santa Barbara and Ph.D. in Genetics from University of California, Berkeley. She completed her postdoctoral fellowship with Dr. Per A. Peterson at The Scripps Research Institute and was a recipient of the Damon Runyon Cancer Research Foundation Fellowship. Subsequently, she held positions at Chiron Corporation as Senior Scientist and at Virologix Corporation as the Director of Viral Research. Followed by her consulting roles to several Pharmaceutical and Biotechnology Companies including a genomics company, Lynx Therapeutics, Inc., she joined Lynx as the Director of Corporate Development in 2000. Subsequently, she was the Director of Business Development and Alliances Management, responsible for initiating, negotiating and managing Lynx's technology development alliances with academic and corporate partners. She was also responsible for managing technology evaluation, scientific licensing and customer support. She joined EGeen in June 2003 and is responsible for overall business development activities at EGeen.
Margus Annuk, Margus Annuk, M.D., Ph.D., Head of Clinical Development and Medical Director
Margus Annuk received his M.D. degree from Tartu University and his Ph.D. degree from University of Uppsala with Prof. Bengt Fellstrom. His extensive research covers the area of renal diseases and transplantation, the field of cardiovascular risk factors (biomarkers), and drug effects on endothelial function, malnutrition, chronic inflammation and antioxidative status. He held a position of Associate Professor at the Tartu University and currently is an adjunct professor of medicine at Tallinn Technical University. He joined EGeen in May 2003 as the Director of Clinical Development to spearhead the clinical development operations.
Jaak Vilo, Ph. D. , Director, Informatics
Jaak Vilo has a M.Sc. in applied mathematics and computer science from Tartu University, Estonia, and a Ph.D. in bioinformatics from the Department of Computer Science, University of Helsinki, Finland. Dr. Vilo worked as a Senior Technologist at the European Bioinformatics Institute EMBL-EBI in the field of microarray based gene expression data analysis and data mining. He has developed several advanced algorithms and tools for the analysis of functional genomics and other complex data and is now heading the informatics department at EGeen.
